0001209191-21-056047.txt : 20210914 0001209191-21-056047.hdr.sgml : 20210914 20210914192501 ACCESSION NUMBER: 0001209191-21-056047 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210914 FILED AS OF DATE: 20210914 DATE AS OF CHANGE: 20210914 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Demetri George CENTRAL INDEX KEY: 0001639147 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38550 FILM NUMBER: 211253744 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORP. STREET 2: 215 FIRST STREET, SUITE 340/350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Translate Bio, Inc. CENTRAL INDEX KEY: 0001693415 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 611807780 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-945-7361 MAIL ADDRESS: STREET 1: 29 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: RaNA Therapeutics, Inc. DATE OF NAME CHANGE: 20161228 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-14 0 0001693415 Translate Bio, Inc. TBIO 0001639147 Demetri George C/O TRANSLATE BIO, INC. 29 HARTWELL AVE LEXINGTON MA 02421 1 0 0 0 Stock Option (right to buy) 10.15 2021-09-14 4 S 0 37800 0.00 D 2029-07-11 Common Stock 37800 0 D Stock Option (right to buy) 15.33 2021-09-14 4 S 0 18900 0.00 D 2030-06-15 Common Stock 18900 0 D Stock Option (right to buy) 20.43 2021-09-14 4 S 0 20000 0.00 D 2031-06-15 Common Stock 20000 0 D As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share. The shares underlying this option are scheduled to vest and become exercisable in equal monthly installments, beginning on August 12, 2019 and ending on the three year anniversary of July 12, 2019. This option was granted on June 16, 2020. The shares underlying this option became fully vested on the date of the Issuer's annual meeting of stockholders following the date of the grant, or June 16, 2021. This option was granted on June 16, 2021. This option will vest and become exercisable in full on the one year anniversary of the date of the award, or if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant. /s/ Paul D. Burgess, as attorney-in-fact for George Demetri, MD 2021-09-14